Abstract:Abstract Introduction: Breast cancer is the primary type of female cancer in the UK. We have recently shown that reduced expression of BMPR-IB correlates with poor prognosis, and may be useful as a prognostic indicator in breast cancer (1). This current study aimed to see if a role for the BMP type II receptor (BMPR-II), also exists in the progression of breast cancer.Methods: Expression of BMPR-II was examined in a cohort of 32 normal breast tissue and 112 primary breast tumour tissue samples. Transcript levels of BMPR-II were then determined using quantitative real time-PCR and protein levels were assessed using immunohistochemical (IHC) staining. Finally, ribozyme transgenes were constructed to knock-down BMPR-II expression in MDA-MB-231 cells. The effect this had in vitro cell growth was examined.Results: In normal breast tissue, IHC staining demonstrated strong expression of BMPR-II, specifically in the epithelial cells. In comparison to the normal breast tissue, reduced expression of BMPR-II was evident in the breast tumour samples. BMPR-II transcript levels were further determined using Q-PCR. A trend was evident in that patients with poor prognosis (0.012±0.09) including those with metastasis, local recurrence and breast cancer deaths, demonstrated reduced BMPR-II expression compared to disease free patients (33±13, p=0.09 vs. poor prognosis). Furthermore, lower expression levels were seen in patient samples with a Nottingham Prognosis Index (NPI) greater than 5.4 (poor prognosis group) (18±17) compared to those with NPI <3.4 (good prognosis group) (41±18, p=0.19). Finally, BMPR-II expression was markedly lower in advanced breast cancer of TNM stage 3 and 4 (0±0.1) compared with those of early stage of the disease (TNM1, 46±17, both p<0.01). Despite the clear trend seen, the majority of the data was not found to be significant, suggesting that unlike BMPR-IB, BMPR-II is less useful in predicting prognosis of breast cancer. However, knocking down BMPR-II expression in MDA-MB-231 breast cancer cell line resulted in a reduction of in vitro cell growth, suggesting BMPR-II may play a positive role in breast cancer cell growth. The absorbance of MDA-MB-231BMPR-IIKO cells at day 5 was 1.29±0.09, p<0.01 compared with MDA-MB-231WT (1.90±0.18) and MDA-MB-231GFP control cells (2.30±0.23).Conclusion: This study reveals a trend for BMPR-II in that its expression appears to be reduced in breast cancer patients with poor prognosis. Despite this, it is not as useful of a prognostic indicator as its type I counterpart BMPR-IB, suggesting that in breast cancer progression, BMPR-IB plays a more important role. However, reduced expression of BMPR-II in MDA-MB-231 resulted in a promotion of cell growth, suggesting that BMPs in breast cancer cells may act via BMPR-II to promote tumour growth. However, this needs further investigation.Reference:1. Bokobza SM, et al. Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. Cancer Genom Proteom, 2009, 6, 101-108 Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3039.

Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.

Bone Morphogenetic Protein 9 Overexpression Reduces Osteosarcoma Cell Migration and Invasion

Enhanced Expression of Type I Receptors for Bone Morphogenetic Proteins During Bone Formation.

Expression of Transforming-Growth-Factor (Tgf)-Beta Receptors and Smad Proteins in Glioblastoma Cell Lines with Distinct Responses to Tgf-Beta 1

Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas.

Identification of Type I Receptors for Osteogenic Protein-1 and Bone Morphogenetic Protein-4.

Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines

Deregulated Bone Morphogenetic Proteins and Their Receptors Are Associated with Disease Progression of Gastric Cancer.

Bone Morphogenetic Protein Receptors and Activin Receptors Are Highly Expressed in Ossified Ligament Tissues of Patients with Ossification of the Posterior Longitudinal Ligament.

The Biological Function of Type I Receptors of Bone Morphogenetic Protein in Bone

Repulsive Guidance Molecules, Novel Bone Morphogenetic Protein Co-Receptors, Are Key Regulators of the Growth and Aggressiveness of Prostate Cancer Cells

Expression of Bone Morphogenetic Protein and Its Receptor in Fibroblastic Osteosarcoma and Malignant Fibrous Histiocytoma and Its Significance in Differential Diagnosis

BMPR-II Mediates Positive Regulation on in Vitro Cell Growth, the Potential Implications for Breast Cancer.

Reduced Expression of BMPR-IB Correlates with Poor Prognosis and Increased Proliferation of Breast Cancer Cells.

Bone Morphogenetic Protein 10 (Bmp-10) Inhibits Growth of Breast Cancer Cells and Correlates with Poor Prognosis

Cloning And Characterization Of A Human Type-Ii Receptor For Bone Morphogenetic Proteins

EXPRESSION OF NERVE GROWTH FACTOR AND ITS RECEPTOR DURING OSTEOINDUCTION OF RECOMBINED HUMAN BONE MORPHOGENETIC PROTEIN 2

The expression of matrix metalloproteinase-2 and-9 in human gliomas of different pathological grades

Gene array analysis of bone morphogenetic protein type I receptor-induced osteoblast differentiation.

Comprehensively Investigating the Expression Levels and the Prognostic Role of Transforming Growth Factor Beta-Induced (TGFBI) in Glioblastoma Multiforme

Expression of RACGAP1 in High Grade Meningiomas: a Potential Role in Cancer Progression